Article
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Cancer discovery - 1 Jun 2017
Hanker Ariella B, Brewer Monica Red, Sheehan Jonathan H, Koch James P, Sliwoski Gregory R, Nagy Rebecca, Lanman Richard, Berger Michael F, Hyman David M, Solit David B, He Jie, Miller Vincent, Cutler Richard E, Lalani Alshad S, Cross Darren, Lovly Christine M, Meiler Jens, Arteaga Carlos L
Abstract excerpt
We report a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization with mutant HER3E928G, also present in the breast cancer, amplifies HER2 signaling. The patient was treated with neratinib and exhibited a sustained partial response....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.